Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemoradiotherapy Combined With Programmed Death 1 Antibody in Recurrent Nasopharyngeal Carcinoma: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

NCT05340491 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05340491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05340491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemoradiotherapy Combined With Programmed Death 1 Antibody in Recurrent Nasopharyngeal Carcinoma: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Recruiting
Start date
April 1, 2022
Completion date
December 31, 2028
Enrollment
212 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma